Novo Nordisk stock gains on China Wegovy approval and expanded buyback
Published on 09/10/2026 at 21:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S stock (ISIN DK0060534915) is trading close to DKK 288.90 on Nasdaq Copenhagen as of September 9, 2026, with investors weighing a landmark China approval for the obesity drug Wegovy and the latest analyst target changes around the shares.
China approval broadens Wegovy’s reach
On September 10, 2026, Novo Nordisk said its blockbuster semaglutide injection Wegovy was approved in China as the first GLP-1 receptor agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis, or MASH, in certain adult patients with moderate-to-severe liver fibrosis.Reuters reports that the company highlighted how evidence of liver health benefits extends Wegovy’s established profile in weight management and cardiovascular health to liver disease, reinforcing its role in comprehensive obesity care.
The Chinese National Medical Products Administration’s decision makes Wegovy the first and only GLP-1 receptor agonist approved in China specifically for MASH, significantly expanding the drug’s potential addressable market in the world’s second-largest pharmaceutical market.VCBeat notes that semaglutide injection can be used for non-cirrhotic adult patients with F2-F3 stage liver fibrosis, adding a new revenue stream beyond obesity and cardiovascular indications.
Analyst targets diverge after the decision
As of September 9, 2026, HSBC increased its price target on Novo Nordisk stock from DKK 300 to DKK 320 while maintaining a Hold recommendation, pointing to upside but also valuation constraints.MarketBeat cites the new target as reflecting Wegovy’s growth prospects, including the expanded opportunity in China’s GLP-1 segment estimated at several billion dollars annually.
According to the analyst overview on Zonebourse dated September 10, 2026, HSBC’s target hike to DKK 320 contrasts with a more cautious stance from Barclays, which lowered its price target from DKK 310 to DKK 300 and reiterated an equal-weight rating after recent news around Novo Nordisk’s pipeline.Zonebourse notes that the HSBC increase of DKK 20 per share implies potential upside of around 11 percent from the DKK 288.90 closing level on Nasdaq Copenhagen, whereas the Barclays reduction narrows expected gains and highlights competitive and pipeline risks.
On the same day, an analyst consensus average target of DKK 310.17 was reported against the DKK 288.90 share price, indicating a smaller implied gain of about 7.36 percent and underscoring that the stock already prices in a considerable portion of Wegovy’s growth story.Zonebourse Investors therefore see China’s regulatory milestone as a fresh catalyst but remain attentive to how quickly the new indication can translate into incremental sales and margins.
Share buyback strengthens capital allocation story
Alongside the China approval, Novo Nordisk continues to support its share price through an extensive buyback programme. Between August 31 and September 4, 2026, the company repurchased an additional 1,055,000 B shares as part of a plan to buy back up to DKK 15 billion of B shares over the 12-month period starting February 4, 2026.The Globe and Mail reports that total purchases under the current programme that began May 6, 2026 reached 17,275,000 B shares with a cumulative value of DKK 5.22 billion over that period.
As of September 4, 2026, Novo Nordisk had repurchased 32,034,179 B shares since February 4, 2026 at an average price of DKK 281.63, for a total transaction value of DKK 9.02 billion, and now holds 46,074,876 B shares as treasury stock, equal to about 1.0 percent of its share capital.Via Ritzau notes that the total share capital stands at around 4,465,000,000 A and B shares, meaning the buyback modestly reduces free float but sends a clear signal on capital allocation discipline.
For investors, these figures show that management is returning substantial capital while the China approval potentially boosts future cash flows: the average repurchase price of DKK 281.63 sits below the recent DKK 288.90 closing level, suggesting the programme has so far been executed at a discount to the latest market price.
Valuation, risks and upcoming drivers
On the US market, Novo Nordisk’s American depositary receipts trade on the New York Stock Exchange under the ticker NVO. As of the close on September 8, 2026, the ADR price was USD 45.16, with an after-hours indication of USD 45.35 at 7:59 p.m. Eastern Time, and a market capitalization around USD 201.40 billion.The Wall Street Journal lists a latest dividend of USD 0.579193 on August 25, 2026 and a dividend yield near 2.88 percent as of September 9, 2026.
MarketBeat data on September 10, 2026 show that NVO stock was trading around USD 44.56 in early trading, compared with USD 50.88 on January 1, 2026, implying a decline of approximately 12.3 percent year to date despite the strong fundamentals of its GLP-1 franchise.MarketBeat also notes that HSBC’s Danish-kroner target of DKK 320 translates into meaningful upside from the current Copenhagen level, even as the US-traded ADR has lagged.
According to a comparative analysis published on Mitrade on September 10, 2026, Novo Nordisk trades on a forward price-to-earnings multiple of about 13.8 times and a price-to-sales ratio close to 3.9 times, compared with higher multiples for some US peers in the biopharma space.Mitrade highlights that Wall Street still expects Novo Nordisk’s sales to decline around 3 percent and net income to contract by about 4 percent in fiscal 2026 as pricing pressure in certain markets slightly erodes margins, a risk investors must weigh against the growth in obesity and liver indications.
Analyst commentary compiled by Zonebourse on September 10, 2026 also mentions that Novo Nordisk recently halted two clinical trials for its cardiovascular candidate ziltivekimab, a setback that raises questions about diversification beyond obesity-focused therapies.Zonebourse notes that this development was one reason Barclays trimmed its target to DKK 300, balancing the Wegovy momentum with pipeline uncertainty.
Stock level and investor takeaway
Per Nasdaq Copenhagen data cited in the recent analyst overview, Novo Nordisk’s B share last closed at DKK 288.90 on September 9, 2026, leaving measured upside to the DKK 320 HSBC target and closer distance to the DKK 300 Barclays target.Zonebourse For investors, the combination of a China MASH approval, ongoing DKK 15 billion buyback and a still-supportive though mixed analyst backdrop keeps Novo Nordisk stock firmly tied to the trajectory of Wegovy and the broader GLP-1 franchise.
Novo Nordisk stock key data
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- Ticker: NVO
- Trading venue: Nasdaq Copenhagen (primary), NYSE (ADR)
- Price (as of September 9, 2026, 17:20): 288.90 DKK
- Market capitalization: 201.40 billion USD (as of September 9, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: OMX Copenhagen 20
